Business Context and Reporting Period
Company: Voyager Therapeutics, Inc. (VYGR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Voyager is a biotechnology company focused on developing genetic medicines for neurological diseases, primarily utilizing its proprietary TRACER™ AAV capsid discovery platform and Voyager NeuroShuttle™ non-viral delivery platform. The company has no approved products and generates revenue solely through strategic collaborations and licensing agreements.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Collaboration Revenue | $40.4 million | $80.0 million | (49.5%) |
| Net Loss | $(119.7) million | $(65.0) million | (84.2%) |
| Operating Expenses | $172.2 million | $163.3 million | +5.5% |
| Research & Development (R&D) | $134.7 million | $127.4 million | +5.7% |
| General & Administrative (G&A) | $37.5 million | $35.9 million | +4.5% |
| Cash, Cash Equivalents, & Marketable Securities | $201.7 million | $320.7 million | (37.1%) |
| Accumulated Deficit | $(445.9) million | $(326.2) million | N/A |
Note: The company reported net income of $132.3 million in 2023 due to significant upfront collaboration revenue recognition.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $39.6 million year-over-year. This was primarily due to the recognition of a $15.0 million fee from the Novartis Amendment in 2024 and higher upfront revenue recognition in 2023. 2025 revenue was driven by proportional performance recognition under Neurocrine and Novartis agreements.
- Increased Net Loss: The net loss widened to $119.7 million from $65.0 million, driven by increased R&D spending and lower collaboration revenue.
- R&D Spend Shifts: R&D expenses increased by $7.3 million. This included a $19.8 million increase in external costs for the anti-tau antibody (VY7523) and tau silencing (VY1706) programs, partially offset by a $13.6 million decrease in the SOD1 silencing program (VY9323) which was discontinued.
- Restructuring: The company executed restructurings in June and December 2025, resulting in $4.3 million in expenses and the termination of 71 employees (41% of the workforce as of Jan 1, 2025).
- Collaboration Adjustments: Novartis partially terminated the 2022 Option and License Agreement in October 2025 regarding two discovery programs, returning rights to Voyager. Neurocrine deprioritized two programs under the 2019 agreement in April 2025.
Guidance, Outlook, and Risks
Outlook and Milestones
- Liquidity: Management expects existing cash ($201.7 million) and expected collaboration reimbursements to fund operations into 2028.
- VY1706 (Tau Silencing Gene Therapy): GLP toxicology study expected in Q1 2026; IND submission anticipated in Q2 2026; clinical trial initiation expected in H2 2026.
- VY7523 (Anti-Tau Antibody): Phase 1 MAD trial initiated in February 2025; initial tau PET imaging data expected in H2 2026.
- Neurocrine FA Program (NBIB-223): Neurocrine intends to initiate a clinical trial in H2 2026 pending IND clearance.
Key Risks and Contingencies
- Capital Requirements: The company has a history of significant losses and will require additional funding. Failure to raise capital could force delays or termination of programs.
- Development Risk: All product candidates are in early-stage development. Preclinical and early clinical data may not predict late-stage success (e.g., competitor Janssen discontinued posdinemab in 2025).
- Collaboration Dependency: Revenue is entirely dependent on partners (Neurocrine, Novartis, Alexion). Partners may terminate agreements or deprioritize programs, as seen with recent partial terminations.
- Regulatory Uncertainty: Changes in FDA policies regarding gene therapy, diversity action plans, and pricing negotiations (IRA) pose significant risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $201.7 million cash balance against the projected burn rate, considering the potential need for additional equity financing before 2028.
- Collaboration Stability: Monitor the status of the remaining active programs under the 2022 Novartis and 2019 Neurocrine agreements following recent partial terminations.
- Clinical Timelines: Track the Q1 2026 GLP toxicology completion for VY1706 and the H2 2026 data readout for VY7523 as critical value inflection points.
- Restructuring Impact: Assess whether the 41% workforce reduction successfully lowers the operating cost base to extend the cash runway.
- Revenue Recognition: Review the proportional performance model assumptions for Neurocrine and Novartis agreements, as changes in expected costs can significantly impact quarterly revenue.